Clinical Trial
Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)
Investigator
Complete title:
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy - the MERKLIN 2 study
Trial phase:
Phase
II
Study ID:
NCT04393753
Local study ID:
RG1121149
Summary:
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody
Trial keywords:
Carcinoma, Merkel Cell
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
For more information about Fred Hutch and to schedule an appointment.
